Answer
Yes, patients treated with Vargatef (nintedanib) have an increased risk of venous thromboembolism, including pulmonary embolism and deep vein thrombosis.
Sources for this answer
- Vargatef 100 mg and 150 mg soft capsulesBoehringer Ingelheim Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 24Document updated
Sources checked